Published in Lab Business Week, September 30th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline.
Report 1: GlaxoSmithKline (GSK) today announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia - CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18. This proposed indication is based on data generated in girls and women aged between 10 and 25.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week